Arcutis Biotherapeutics, Inc. ARQT

$ARQT don’t be surprised to see it skyrocket pre market one day. Things are in motion.

“We believe the expanded derm sales effort, new PCP/peds team, and telehealth platform provide the key levers for Zoryve to continue its growth momentum into 2027,” Belanger wrote, maintaining his Buy rating and $40 target.

Jefferies analyst Andrew Tsai agreed. Strong underlying demand, helped by a 30-person PCP/PED salesforce and a new Simone Biles-led DTC campaign, should drive TRx volumes higher in early 2027,” Tsai wrote with his Buy rating and $39 target unchanged.

$ARQT

Buy the dip fools

That’s how Wall Street makes money, some one yells boo and the retail shake thier boots and run and they buy it cheap.

50-60$ EOY $ARQT

Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
Arcutis Biotherapeutics, Inc.
October 06, 2026 08:19 ET
Newly created award category highlights innovation in prescription skin treatment
ZORYVE cream 0.15% for mild to moderate atopic dermatitis (eczema) in adults and children 6 years of age and older is first medication to win the award
ZORYVE is the number one prescribed branded topical therapy across three major inflammatory skin conditions combined — eczema, plaque psoriasis, and seborrheic dermatitis

Becoming a profitable company, see you at the earnings $ARQT

$ARQT see you at 40$ :)

$ARQT Over the past 90 days, the Zacks Consensus Estimate for ARQT's full-year earnings has moved 35.7% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, ARQT has gained about 202.5% so far this year. At the same time, Medical stocks have gained an average of 5.6%. This means that Arcutis Biotherapeutics, Inc. is outperforming the sector as a whole this year.

$ARQT ARQT Sales Forecast
Next quarter’s sales forecast for ARQT is $36.36M with a range of $35.70M to $38.00M. The previous quarter’s sales results were $30.86M. ARQT beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.76% of the time in the same period. In the last calendar year ARQT has Outperformed its overall industry.